Luc J. Derijks

Maastricht, LI, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Influence of Ageing on the Pharmacology, Efficacy and Safety of Oral Targeted Therapies for Inflammatory Bowel Disease: Focus on Janus Kinase (JAK) Inhibitors and Sphingosine-1-Phosphate (S1P) Receptor Modulators.

Influence of Ageing on the Pharmacology, Efficacy and Safety of Oral Targeted Therapies for Inflammatory Bowel Disease: Focus on Janus Kinase (JAK) Inhibitors and Sphingosine-1-Phosphate (S1P) Receptor Modulators.

Journal: Drugs & aging

Published: April 07, 2026

Retrospective Validation of Clinical Decision Support Tools for Predicting Effectiveness Outcomes in Inflammatory Bowel Disease Patients Treated with Vedolizumab.

Retrospective Validation of Clinical Decision Support Tools for Predicting Effectiveness Outcomes in Inflammatory Bowel Disease Patients Treated with Vedolizumab.

Journal: Pharmaceutics

Published: November 04, 2025

The decline of 6-thioguanine nucleotides is not linked to impaired efficacy or safety of thiopurines in pregnant women with inflammatory bowel disease.

The decline of 6-thioguanine nucleotides is not linked to impaired efficacy or safety of thiopurines in pregnant women with inflammatory bowel disease.

Journal: British journal of clinical pharmacology

Published: October 01, 2025

Simulated Dosing Regimens of Subcutaneous Infliximab in Adults and Children with Inflammatory Bowel Disease: Exploring Switch and Initiation Strategies.

Simulated Dosing Regimens of Subcutaneous Infliximab in Adults and Children with Inflammatory Bowel Disease: Exploring Switch and Initiation Strategies.

Journal: European journal of drug metabolism and pharmacokinetics

Published: July 07, 2025

6-mercaptopurine and tofacitinib alter microbial protein expression but not composition in fecal microbiota incubations from Crohn's disease patients.

6-mercaptopurine and tofacitinib alter microbial protein expression but not composition in fecal microbiota incubations from Crohn's disease patients.

Journal: BMC biology

Published: June 16, 2025

Population Pharmacokinetics Model of Thioguanine in Patients with Inflammatory Bowel Disease.

Population Pharmacokinetics Model of Thioguanine in Patients with Inflammatory Bowel Disease.

Journal: Clinical pharmacokinetics

Published: May 15, 2025

Therapeutic Drug Monitoring and Pharmacogenomics of Thiopurines in Inflammatory Bowel Disease: International Guidelines Revisited.

Therapeutic Drug Monitoring and Pharmacogenomics of Thiopurines in Inflammatory Bowel Disease: International Guidelines Revisited.

Journal: Therapeutic drug monitoring

Published: March 17, 2025

The fate of thiopurine metabolites after switching to low-dose thiopurine with allopurinol or thioguanine in IBD patients: A retrospective analysis.

The fate of thiopurine metabolites after switching to low-dose thiopurine with allopurinol or thioguanine in IBD patients: A retrospective analysis.

Journal: British journal of clinical pharmacology

Published: January 21, 2025

Comment on: A Soaring Price, a Silent Fight: Thioguanine Portends New Access Barriers to Life-Saving Treatments for Children With Cancer: The Ugly Duck or The Chicken with the Golden Eggs: The Crisis in Thioguanine Accessibility.

Comment on: A Soaring Price, a Silent Fight: Thioguanine Portends New Access Barriers to Life-Saving Treatments for Children With Cancer: The Ugly Duck or The Chicken with the Golden Eggs: The Crisis in Thioguanine Accessibility.

Journal: Pediatric blood & cancer

Published: November 13, 2024

The Use of Tissue Concentrations of Biological and Small-Molecule Therapies in Clinical Studies of Inflammatory Bowel Diseases.

The Use of Tissue Concentrations of Biological and Small-Molecule Therapies in Clinical Studies of Inflammatory Bowel Diseases.

Journal: Pharmaceutics

Published: October 17, 2024

Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease.

Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease.

Journal: Clinical pharmacokinetics

Published: February 04, 2024

Genetic association analysis and frequency of NUDT15*3 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease in a large Dutch cohort.

Genetic association analysis and frequency of NUDT15*3 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease in a large Dutch cohort.

Journal: The pharmacogenomics journal

Published: January 25, 2024

Showing 1-12 of 52

Last Updated: 09/26/2026